Objective: To estimate, from a Filipino societal perspective, the costeffectiveness of preventing atopic dermatitis (AD) via early nutritional intervention with 100% whey-based partially hydrolyzed formula (PHF-W) versus standard cow's milk formula (SF) in healthy, urban infants with atopic heredity who are not exclusively breast-fed. Methods: A Markov model was used to simulate over 6 years the incidence of AD, days with AD symptoms, quality-adjusted life-years (QALYs), and AD-related direct and indirect (i.e., parents'/caregivers' productivity loss) costs incurred by hypothetical cohorts of healthy, at-risk infants fed with either PHF-W or SF as AD prevention for ≤ 17 weeks. Efficacy estimates of PHF-W versus SF in preventing AD were literature-based. The resources used to manage AD (by severity, age, and treatment modality) were estimated using clinical pathways derived from clinical expert opinion. Local costs were applied to resource use. Results were presented as point estimates and as 95 percent credible intervals (CIs, i.e., range of values around the point estimate that include 95% of model simulations) generated via multivariate probabilistic sensitivity analysis using Monte-Carlo simulation techniques. All costs are reported in Philippines pesos (₱, where ₱1000 ¼ US $22.24). All reported outcomes were discounted at a rate of 3.5% per year. Results: Based on the 6-year simulation, compared with SF, PHF-W was predicted to result in a 14-percentage point reduction (i.e., 39% vs. 25%) (95% CI 0.09-0.19) in the incidence of AD and a gain of 0.03 (i.e., 5.46 vs. 5.43) (95% CI 0.01-0.07) QALYs/patient. PHF-W's higher feeding formula cost (þ₱1,304/patient) (95% CI À₱3,090 to ₱5,779) were offset by reductions in AD-related costs (À₱11,959/ patient; i.e., ₱27,228 vs. ₱15,269) (95% CI À₱14,685 to À₱7,284), including, in particular, the costs of pharmacotherapy, formula used as treatment, and visits to physicians. As a result, PHF-W became a net cost-saving strategy within 38 weeks. Overall, PHF-W resulted in net savings of À₱10,654 (ÀUS $237) (CI À₱4,240 [ÀUS $94] . Sensitivity analysis confirmed the robustness of results; the most influential variable was the first-year risk reduction in AD. Conclusions: Based on the present modeling exercise, compared with SF, PHF-W appears to substantially reduce the risk of AD and its associated direct and indirect medical costs in healthy, at-risk urban Filipino infants over a 6-year period.
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Introduction
Atopic dermatitis (AD) is one of the most common inflammatory skin disorders affecting infants and young children [1, 2] . The economic and quality-of-life (QOL) burden imposed due to AD on patients, families, and societies has recently increased globally as a result of increasing prevalence of AD, its chronic nature, and association with other atopic diseases [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .
A combination of genetic, immunologic, and environmental factors affect a child's risk of developing AD. Evidence suggests that early (i.e., within the first 6 months of life) exposure to dietary allergens, such as proteins found in standard cow's milk formula (SF), can increase the risk of AD. Reasons such as this have led the World Health Organization to recommend exclusive breast-feeding through the first 6 months of life [14] [15] [16] . Unfortunately, despite best efforts, this recommendation is not or cannot always be followed. In such instances, infants may be fed with SF as a nutritional supplement to breast milk and, as a result, are exposed to a higher risk of AD.
Breaking down SF proteins into smaller peptides can reduce immunogenicity [17] . This has led to the development of hydrolyzed formulas as an alternative to SF for infants who are not exclusively breast-fed for the first 6 months of life [17] . Depending on the degree to which the proteins are hydrolyzed, these formulas are known as partially hydrolyzed formula (PHF) or extensively hydrolyzed formula (EHF) and can contain whey (W) and/or casein (C) as a source of protein. In some populations, such as healthy infants with atopic heredity who are not exclusively breast-fed, the use of these hydrolyzed infant formulas has been shown to reduce the incidence of AD and other allergies [18] [19] [20] . In particular, the German Infant Nutritional Intervention (GINI) study randomized nonexclusively breast-fed newborns with atopic heredity to SF or a partially hydrolyzed whey formula (PHF-W) for their first 17 weeks of life. After 6 years, infants who received PHF-W experienced a lower cumulative incidence of AD relative to those receiving SF (adjusted relative risk [RR] ¼ 0.64; 95% confidence interval [CI] 0.48-0.86) [18] .
The primary prevention of AD with PHF-W in at-risk populations may result in clinical and QOL benefits, as well as reduced health care costs. However, these benefits must be weighed against the potentially higher costs of PHF-W relative to SF during the 17-week interventional period. Several economic studies conducted in developed countries, such as Australia, Germany, Denmark, Switzerland, and France, suggest that PHF-W is cost-effective if not outright cost-saving compared with SF in at-risk infants who are not exclusively breast-fed [8, 17, [21] [22] [23] [24] [25] [26] . However, a search of the literature indicates that no comparable evidence exists in developing nations.
The aim of the present study was therefore to estimate from the perspective of a non-Western country (i.e., the Republic of the Philippines) the cost-effectiveness of preventing AD via early nutritional intervention with PHF-W versus SF as milk substitute in urban, healthy infants with atopic heredity who are not exclusively breast-fed. The Republic of the Philippines was selected as a case study because 1) its level of development is typical of lower middle-income countries and 2) the cumulative incidence of AD in late childhood in the Philippines is representative of the Southeast Asia region [27] despite anecdotal evidence that Filipinos may be predisposed to AD [28] .
Methods

Overview
Decision analytic techniques were used to compare the cost effectiveness of PHF-W vs. SF in the first 17 weeks of life as primary prevention of AD among healthy, at-risk, Filipino infants from urban areas who are not exclusively breast-fed.
Consistent with the GINI study [19] , infants were defined as at risk if they had one or more parent or sibling diagnosed with reported allergic manifestations. The analysis adopted a societal perspective and included estimates of direct medical (out-of-pocket costs for the infant formula, treatments, clinic visits, hospitalization) and indirect (parents'/caregivers' productivity loss) costs associated with the prevention and treatment of AD regardless of the party ultimately responsible for these costs. The analytical horizon included the first 6 years of life, consistent with the GINI study [18] .
Model Structure
A Markov model was built (in Microsoft Excel, Microsoft Co., Redmond, WA) to follow hypothetical cohorts of infants receiving either PHF-W or SF. Each cohort was followed in weekly cycles from birth to year 6 or death, whichever came first. A simplified, graphical presentation ( Fig. 1) shows healthy, at-risk infants (i.e., without AD) entering the model at birth (see in Fig. 1A) . At that point, infants initiate PHF-W or SF (see in Fig. 1B ) for 17 weeks as needed as supplement or a substitute to breast milk. Thereafter, unless an AD episode is experienced, all patients were assumed to be on SF until month 24 in quantities depending on the age and nutritional needs (see Appendix A in Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.2014.04.001). From month 24 to year 6, no infant formula was used (i.e., children were assumed to meet their entire nutrition requirements from other sources, such as solid food).
The risk of AD varied according to age and the type of formula received during the prevention period. If and when a child experienced an initial AD episode (see in Fig. 1C ) (stratified by severity, defined according to the SCORing Atopic Dermatitis, score of mild, moderate, or severe) [29] , three treatment modalities were used: a switch to soy formula only (see in Fig. 1D) ; a switch to soy formula along with first-line pharmacotherapy (see in Fig. 1E ); or addition of a first-line pharmacotherapy only (see in Fig. 1F ) (details of pharmacotherapy and infant formula used in each line of treatment are provided in Appendices B-D in Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.2014.04.001). The inclusion of these modalities and their associated treatment algorithms were based on the opinion of three Filipino clinicians with extensive experience in treating urban pediatric patients with AD (including two of the authors R.R.H.G. and M.V.C.D.) and the approach used in the previous models [8, 17, [21] [22] [23] [24] [25] [26] ]. In the model, patients were assigned to each treatment modality depending on the severity of AD and age (i.e., the pharmacotherapy-only approach was used after month 24 because formula was not consumed thereafter) (see Appendix E in Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.2014.04.001).
The success of each treatment approach (i.e., response rates, defined as recovery from the rashes associated with AD) determined how fast AD symptoms would be resolved and hence how fast a child with AD would be in an AD-controlled state (ADCS). These response rates to pharmacotherapy and formula replacement therapy were assessed after 1 and 2 weeks, respectively, and were dependent on the type of therapy and AD severity. Patients who responded to switches in formula (e.g., from PHF-W or SF to soy) were assumed to continue the new formula until month 24, death, or the next AD episode; however, patients who responded to pharmacotherapy were assumed to discontinue the pharmacotherapy at the end of the treatment course but to remain on their formula.
In the initial treatment of AD with a switch to soy formula only (see in Fig. 1D ), a patient could experience a response and be in ADCS (see in Fig. 1G ) on soy-based formula. If a response was not observed, the soy formula was switched to casein-based extensively hydrolyzed formula (EHF-C) (see in Fig. 1H ). In case of response to EHF-C, the patient would be considered to be in ADCS (see in Fig. 1I ) and would remain on EHF-C. In case of nonresponse, a pharmacotherapy would be added (see in Fig. 1J ). For simplicity, it was assumed that a response would be achieved at this stage and the patient would be in ADCS (see in Fig. 1I ). In the case that a first AD episode was treated with a switch to soy formula combined with the use of a first-line pharmacotherapy (drug 1) (see in Fig. 1E ) and response occurred within a week, pharmacotherapy would end and the patient would be considered to be in ADCS on soy formula (see in Fig. 1G ). However, in case of nonresponse, the formula would be switched to EHF-C (while pharmacotherapy would remain the same) (see in Fig. 1K ). For simplicity, it was assumed that response would be obtained with this approach and the patient would be in ACDS with EHF-C (see in Fig. 1I ). Last, patients treated exclusively with a first-line pharmacotherapy (see in Fig. 1F ) could respond (in which case
they would enter the ADCS on the original formula [SF or PHF-W]) (see in Fig. 1L ) or not. In the latter, the patients would be switched to a second-line (see in Fig. 1M ), third-line (see in Fig. 1N ), and fourth-line (see in Fig. 1O ) therapy until response, in which case pharmacotherapy would be discontinued and the patient would be in ADCS on the initial formula (see in Fig. 1L) .
The model also included the risk of flares (i.e., relapses, indicated by a dashed arrow on Fig. 1 ) after initial remission from the initial AD episode (i.e., after entering any ADCS). The relapse risk was dependent on age and severity of the initial AD episode. Children in ADCS and on soy formula (see in Fig. 1G ) who experienced a relapse were treated either via an addition of first-line pharmacotherapy (see in Fig. 1E ) or a switch of formula to EHF-C (see in Fig. 1H ) or EHF-C with first-line pharmacotherapy (see in Fig. 1K ). From these states, the treatment patterns followed the algorithms already described above. Children in ADCS on EHF-C (see in Fig. 1I ) were assumed to be treated with first-line pharmacotherapy (see in Fig. 1J ). Finally, children in ADCS and still on their original formula (whether SF or PHF-W) (see in Fig. 1L ) were assumed to be treated with either a change in formula or pharmacotherapy or both. Once back into the respective ADCS, patients continued to be at risk for another episode.
Finally, the general population mortality was included in the model by using published life tables for the Philippines [30] (not shown in Fig. 1 ). This was done to account for the fact that the early investment in PHF-W could be lost in case of premature death.
Epidemiologic and Clinical Inputs
The weekly probability of AD for SF, stratified by age categories, was obtained via linear interpolation of the 1-, 3-, and 6-year cumulative incidence data from the GINI study [19] 
above by the adjusted RR for PHF-W observed in the GINI study (i.e., 0.64, 95% CI 0.48-0.86).
The distribution of AD cases and probability of flares by severity (mild, moderate, and severe) and by age group (0-2 years; 2-6 years) (Table 1) , the type of treatment modality by severity and age (Appendix E in Supplemental Materials found at http:// dx.doi.org/10.1016/j.vhri.2014.04.001), and their corresponding response rates (by line of therapy) ( Table 2) were derived on the basis of the opinion of the three clinical experts involved in the study. The duration of AD flares (including the initial episode) was calculated on the basis of the weekly probability of response.
Utility Inputs
It was assumed that children without history of AD experienced a full utility (¼1.000) ( Table 3) . It was further assumed that any child in ADCS had a utility slightly less than 1.000 (i.e., 0.980) to recognize that very mild, subclinical episodes of AD could reduce a child's QOL. The utilities associated with an ongoing mild, moderate, and severe AD episode were 0.863, 0.690, and 0.450, respectively, on the basis of previously published data [31, 32] . Finally, death was associated with a utility of zero.
Resource Use and Cost Inputs
The daily intake of the infant formula was calculated as described in Iskedjian et al. [24] and took into consideration the quantities applicable as result of partial breast-feeding (Appendix A in Supplemental Materials found at http://dx.doi.org/10.1016/j. vhri.2014.04.001). Infant formula is not covered by private or public insurance companies in the Philippines; therefore, it was assumed that the cost of infant formula would be paid as an outof-pocket expense by families. The acquisition prices of infant formula (Table 4) were obtained from one of the largest pharmacy chains in the Philippines (i.e., Mercury Drug Stores). Because infants would be fed with formula when not exclusively breastfed, only the additional cost that would be incurred as a result of feeding with alternative infant formula (such as PHF-W, soybased formula, EHF-C, and amino acid-based formula) as opposed to SF was included in the analysis. . For the parameters defined by three levels of severity (mild, moderate, and severe), three gamma distributions were generated (one for each level) before normalizing these three percentage to ensure that the sum of probabilities is equal to 1. Because of the missing sample size information, alpha and beta here are derived from the original percentage inputs, assuming the sample size was 100. AD, atopic dermatitis; PHF-W, partially hydrolyzed whey formula; PSA, probabilistic sensitivity analysis; SF, standard cow's milk formula; uSA, univariate sensitivity analyses; y, year. * Because of lack of data sources, some value inputs were based solely on arbitrary variation, rather than the distribution assumption in the PSA, to test the univariate sensitivity. † Source: von Berg et al. [18] . ‡ Source: Expert panel. § The probability of moderate AD is calculated as a residual of all cases and dependent on the upper/lower inputs of mild and severe cases: e.g., probability (moderate) ¼ 1 À probability (mild) À probability (severe). Thus, it is not varied in the uSA. || Mortality data for children younger than 5 y, specific to the Philippines (Source: World Bank data).
The three clinical experts also provided information on the type and amount of resources used with each treatment modality. Specifically, the frequency of pediatrician, specialist, and inpatient visits was dependent on the severity of AD and the response to therapy (Appendix B in Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.2014.04.001). Based on clinical expert opinion, hospitalizations were assumed to occur in 5 out of 100 patients with severe AD on the initial development of AD. The costs of visits were obtained from a Nestlé country affiliate.
Almost all patients with AD were prescribed emollient cream and corticosteroid cream on the initial development of AD and then again during reassessment consultation visits every 2 weeks in case of no response. The prices of all the medicines were . For distribution of type of therapies provided (switch formula, combined, medical), three gamma distributions were generated (one for each level) before normalizing these three percentage to ensure that the sum of probabilities is equal to 1. Because of the missing sample size information, alpha and beta here are derived from the original percentage inputs assuming the sample size was 100. AD, atopic dermatitis; PSA, probabilistic sensitivity analysis; uSA, univariate sensitivity analyses; y, year. * Source: Expert panel.
† Because of lack of data sources, some value inputs were based solely on arbitrary variation, rather than the distribution assumption in the PSA, to test the univariate sensitivity. ‡ The probability of combined treatment of AD is a residual state of all treatment and dependent on the upper/lower inputs of switch formula and medical treatment; e.g., probability (combined) ¼ 1 À probability (medical) À probability (switch formula). Thus, it is not varied in the uSA. § The percentage of patients with AD treated using combined treatment strategy were assumed to be a residual percentage of patients treated with formula switch and medical treatment.
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obtained from one of the largest pharmacy chains in the Philippines (i.e., Mercury Drug Stores) ( Table 4) .
Diagnostic tests were performed in laboratory only for some patients with moderate or severe AD manifestation. Prick test, specific immunoglobulin E (IgE) test, and food elimination tests were performed only once on the initial development of AD depending on the severity of AD. The cost of these diagnostic tests was obtained from a Nestlé country affiliate (Table 4) . Reduced productivity (indirect costs) included lost workdays to care of children with AD following the initial physician visit (irrespective of the severity of AD) on the development of AD.
Outcome Measures and Analyses
Using the data on the incidence of AD, recurrence of AD, and duration of AD episodes, it was possible to estimate the 6-year per-patient risk of AD and the expected number of days with AD symptoms. Incremental cost-effectiveness ratios were computed to estimate the relative economic value of PHF-W versus SF, including the incremental cost per AD case avoided, incremental cost per day without AD symptoms gained, and incremental cost per QALY gained.
In addition to the base-case analysis, various sensitivity analyses were carried out to evaluate the robustness of the results. First, deterministic univariate sensitivity analyses were conducted on individual model parameters while keeping the base-case values for other parameters in the model unchanged (see Tables 1-4 for ranges tested). Scenario analyses were conducted to test the effects of changing key model assumptions either alone or in combination. These included omitting any flares from the analysis, restricting the analysis to 1 year (as opposed to the 6-year time frame), assuming no mild AD cases seek or receive treatment, or assuming a 6-year cumulative incidence rate of 8.4%, based on epidemiologic data reported in the International Study of Asthma and Allergies in Childhood (ISAAC) for Filipino children irrespective of atopic heredity and formula received [27] .
Finally, multivariate, probabilistic sensitivity analyses (PSA) were conducted whereby the models were run 5000 times via Monte-Carlo simulation techniques to estimate bootstrapped 95% credible intervals (95% CI) (i.e., percentile distributions [2.5th and 97.5th]). All results were reported after applying a discount rate of 3.5% to all costs and QALYs beyond year 
Results
Base Case
Compared with SF, primary prevention of AD with PHF-W resulted in a 14-percentage point reduction in the incidence of AD (i.e., 39% vs. 25%) (95% CI 0.09-0.19), a reduction of 22 days with AD symptoms (95% CI 14-26), and a gain of 0.03 QALYs/ patient (i.e., 5.46 vs. 5.43) (95% CI 0.01-0.07) ( Table 5 ). The higher formula cost of PHF-W (þ₱1,304/patient) was offset by reductions in AD-related costs (À₱11,958/patient) (i.e., ₱27,228 vs. ₱15,269). PHF-W became a net cost-saving strategy within 38 weeks (Appendix H in Supplemental Materials found at http://dx.doi. org/10.1016/j.vhri.2014.04.001). The total costs were primarily driven by the costs associated with pharmacological treatments (Fig. 2) . The total cost savings was À₱10,654 (ÀUS $237) (95% CI À₱14,545 [ÀUS $323] to À₱4,240 [ÀUS $94]) over the 6-year time horizon. Estimated incremental cost-effectiveness ratios (ICERs) indicated PHF-W to be a net saving strategy while at the same time resulted in reductions in AD cases, days with AD symptoms, and gains in QALY. Hence, PHF-W was considered a "dominant" strategy relative to SF (Table 5) .
Sensitivity Analyses
Multivariate PSA results indicated that PHF-W was dominant (more effective and less expensive) in all 5000 model runs. Fig. 3 presents a tornado diagram summarizing the univariate sensitivity analyses results for the 15 most sensitive parameters in the model. The highest variations in the net cost savings were observed when the RR (cumulative incidence) of the development of AD up to 1 year was modified. Specifically, when the RR (cumulative incidence) of the development of AD up to 1 year was varied between 34% and 87%, the resulting net savings with PHF-W ranged from À₱13,597 to À₱5,728, respectively. The next most influential variables were the proportion of mild cases below age 2 years, the PHF-W unit cost, the RR (cumulative incidence) of the development of AD up to 3 years, and the SF unit cost. PHF-W remained the dominant interventional strategy for the prevention of AD in all tested univariate sensitivity analyses.
Finally, in scenarios analyses (Table 6 ), the PHF-W strategy ceased to be a dominant strategy over SF when the following conditions were met: when relapses were omitted from the [32] .
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analysis altogether, when the 6-year cumulative incidence of AD was assumed to be low (i.e., 8.4% as reported in ISAAC [27] for children with and without atopic heredity and irrespective of formula feeding), or when the analytical horizon was limited to 1 year (instead of 6). PHF-W was considered cost-effective relative to SF as long as relapses were included, except in the case the incidence of AD was low. When relapses were omitted, PHF-W was considered cost ineffective relative to SF when the incidence rate was low and the analytical perspective was 1 year. When only the relapses were omitted (and the other parameters were similar to the base case), PHF-W was considered costeffective (and cost savings) relative to SF. In the intermediate situations in which relapses were omitted and either the incidence is low with the 6-year analytical perspective or the analytical perspective is short (i.e., 1 year) but the incidence is as assumed in the base case, the incremental cost-effectiveness ratios were slightly above ₱300,000 and may be considered borderline costeffective for an urban population (with, for instance, an income per capita in the metro Manila area of ₱180,000; Sources: Republic of the Philippines, Philippine Statistics Authority, and National Statistical Coordination Board: http://www.nscb.gov.ph/grdp/2012/ perCapitaGRDP.asp, last accessed April 3, 2014). Singapore) were used on the basis of availability and market share in the Philippines. ‡ Prices obtained from Mercury Drug Stores, largest pharmacy chain in the Philippines. § Recommended quantities from the package inserts were used to determine quantity of formula for daily consumption. The complete breakdown of quantity of formula consumed per day available on request from the authors. || Upper and lower inputs value for the uSA were based on price ranges of market brands available; values for the PSA assume uniform distribution and take the symmetric opposite of the upper value as the lower bound.U[x 1 ,x 2 ] ¼ Uniform distribution ranging from value x 1 to x 2. ¶ Source: Based on average fees charged in Philippines. # Costs associated with the time loss were estimated using average hourly wages in the Philippines (₱187), labor force participation (65%), correction for cost-elasticity (80%), and the hours spent (16 h, i.e., 2 work days) while taking care of a child after the initial development of AD. ( 2 0 1 4 ) 1 2 4 -1 3 5 Table 5 -Base-case results.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C
Outcomes
SF arm PHF-W arm Difference Fig. 2 -Six-year cumulative costs* with SF and PHF-W cohorts. Note: The formula prevention and formula treatment costs are only the excess cost over and beyond the cost of feeding using SF. PHF-W, partially hydrolyzed whey formula; SF, standard cow's milk formula. *₱1000 ¼ US $22.24.
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Discussion
A search of the Medline-indexed literature indicates that the present analysis may be the first to have assessed the costeffectiveness of PHF-W versus SF in the Republic of the Philippines (and in any developing country). It is also one of the few cost-utility analyses ever conducted in the Philippines. In the present analysis, early nutritional intervention with PHF-W as replacement for cow's milk formula in healthy infants with atopic heredity who are not exclusively breast-fed appears cost-effective and in fact dominant (i.e., less expensive and more effective) compared with SF. In the base-case analysis over a 6-year period, PHF-W resulted in reductions in the risk of AD (39% vs. 25%, a relative reduction of 36%) and days with AD symptoms (from 50 to 28) and in an increase in QALYs of 0.03 (5.46 vs. 5.43). As a result, the use of PHF-W also resulted in net cost savings of ₱10,654 (US $237) per infant (from ₱27,228 [US $606] to ₱16,574 [US $369]), after including the additional cost of PHF-W over SF. The analysis also showed that, within 38 weeks, the initial -P14,000 -P12,000 -P10,000 -P8,000 -P6,000
Relative Tables 1-3 ) affect the cost difference (cost of PHF-W arm minus cost of SF arm). For example, when the relative risk (cumulative incidence) of the development of AD up to 1 year was varied between 34% and 87%, the resulting net savings with PHF-W were À₱13,597 and À₱5,728, respectively. AD, atopic dermatitis; EHF-C, extensively hydrolyzed casein formula; hi, high; lo, low; PHF-W, partially hydrolyzed whey formula; SF, standard cow's milk formula; yr(s), years(s).*₱1000 ¼ US $22.24. AD, atopic dermatitis; PHF-W, partially hydrolyzed whey formula; QALY, quality-adjusted life-year; y, year. * ₱1000 ¼ US $22.24.
† Dominant: PHF-W is less expensive and more effective than SF.
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investment in additional formula cost was offset by reduction in AD-related treatment costs. The robustness of these results was confirmed via various sensitivity analyses, including univariate, multivariate, and scenario analyses. To some degree, these findings are not surprising. Indeed, the absolute difference in risk of AD over 6 years was approximately 14% (consistent with the cumulative results of the GINI study). This reduction is achieved at a relatively modest investment: if one assumes 17 weeks of feeding with PHF-W at the dosages and nutrition needs used in the model, then the extra cost of PHF-W (compared with SF) is approximately ₱1,319 (i.e., 17 weeks Â 7 days Â 80.45 g/d Â [₱974 À ₱850]/900 g). Hence, cost neutrality of PHF-W with SF will be achieved if the average lifetime AD-related costs of treating a patient with AD are greater than ₱9,421 (i.e., ₱1,319/14%). In the present analysis, based on the assumptions used in the model, it would appear that the lifetime cost of treating a patient with AD is approximately ₱80,000, or about 8 times as high as this breakeven point of ₱9,421.
As shown in Fig. 2 , the difference in costs between the two arms of the model are driven by three categories of costs, namely, the cost of pharmacotherapy, the cost of formula (as treatment of AD), and the costs of physician visits. The indirect costs and the other direct costs (laboratory, diagnostics, and hospitalizations) had less of an effect. The cost of pharmacotherapy tends to be high because it is by far the most common treatment method as it is included alone or in combination with formula change in 95% of the cases. The cost of formula as treatment method is high because despite being used less often, once switched to a new formula (following a flare), a child was assumed to remain on this new modality until no formula is used. Finally, the cost of visits is relatively expensive because the cost per visit was itself assumed relatively high. In addition, the model includes the assumption that the hallmark of AD is the frequent recurrence of flares. To see how the assumptions regarding the recurrence of flares affect the results, a scenario analysis was conducted in which no relapse would be included. In this case, the net cost difference between the two treatment arms was reduced from À₱10,654 to À₱438.
The conclusions of the present analysis are consistent with those generated by similar analyses in Western countries, including France [24] , Germany [21, 22] , Switzerland [23] , and Australia [17] . In each of these countries, the use of PHF-W was alternatively cost-effective or cost saving (depending on whether one adopted a third-party payer or a societal perspective). The consistency in model results could be expected given that the present analysis followed many (albeit not all) of the methods used in the previous work [17, [22] [23] [24] . However, the present analysis differs from these previous studies in that it included a 6-year perspective (others adopted a perspective r3 years); included a more detailed analysis of recurrence scenarios; focused exclusively on the GINI data as the source of efficacy (previous studies typically used a meta-analysis [25] of GINI and other studies); and, importantly, included QALYs. In this respect, the present analysis is closer to the work by Mertens et al. [8] , who included a 6-year perspective, used not only the GINI study but also included other allergic manifestations such as asthma, and the work by Erdogan Ciftci et al. [22] , who, in their analysis focusing on Germany, used a 6-year perspective and detailed recurrence information, relied only on the GINI study, and included QALYs.
One of the challenges of this analysis was the lack of published data from the Philippines on the epidemiology of AD, the clinical effectiveness of PHF-W versus SF in the prevention of AD, and the treatment patterns of AD in the Philippines. As a result, the present analysis relied heavily on the results of the GINI study. In addition, the treatment patterns and the assumptions about the effectiveness of the various AD treatment modalities were derived largely from the clinical opinion of two of the authors and one additional clinician. However, this challenge is not unique to the Philippines. In both developed and developing countries, AD is diagnosed clinically and its severity is assessed subjectively. It is not routinely recorded administratively (e.g., for reimbursement). Hence, in many nonprospective studies, the severity of AD cannot be asserted definitely. Many of the treatments used for AD involve the use of out-of-pocket expenses (such as formula replacement or the use of over-the-counter moisturizing creams and other ointments) borne by families. These resource uses are largely under-recorded and can be difficult to estimate. As a result, even the above-mentioned analyses conducted in Western countries [8, 17, [21] [22] [23] [24] [25] [26] largely relied on the evidence and methods of data collection also used in the present analysis.
Nevertheless, one may attempt to contrast the assumptions made in the present analysis to the limited data reported in the literature pertaining to the Philippines. In the present analysis, it has been assumed on the basis of data from the GINI study that the cumulative incidence of physician-diagnosed AD in at-risk infants (i.e., those with atopic heredity who are fed with SF as partial or full supplement to breast milk) was 16.8% by year 1, 33.5% by year 3, and 39.1% by year 6. In a study comparing the incidence of clinical allergic manifestations in 110 Singaporean infants with a positive family history of atopy and who were not breast-fed indicated that the cumulative incidence of AD was 43.9% by the age of 2.5 years among those who were fed with cow's milk-based formula and 28.3% for those fed with PHF-W, supporting the results of the present study [33] . In contrast, ISAAC found that the cumulative incidence of eczema in all children, irrespective of atopic heredity and formula feeding, by age 6 to 7 and 13 to 14 years in Germany, was 14.7% and 13.6%, respectively [27] . Corresponding data for the Manila metropolitan area were not available for children aged 6 to 7 years but in those aged 13 to 14 years, the incidence was 8.4% [27] . Corresponding rates for Malaysia, Indonesia, Singapore, and Vietnam ranged from 2.8% to 8.2% and 5.5% to 12.3% for the younger and older age groups, respectively. Two obvious observations can be made on the basis of the above data: 1) as would be expected, the cumulative incidence of AD within the same country (i.e., Germany) does appear much larger in children with atopic heredity who are fed with SF as partial or full supplement to breast milk (as in the GINI study) than in the general population (as in ISAAC); 2) the cumulative incidence of AD in the Philippines and neighboring countries may be somewhat less than that observed in Germany. These findings also point to a great degree of variability across countries. Few other relevant estimates of the incidence of AD exist. Only one largely anecdotal study [28] from a single pediatrician practice in San Diego, CA, was found to report on the prevalence of AD in patients of Filipino descent. In this study, the frequency of AD diagnosis was highest (8.54%) among Filipino children younger than 18 years (irrespective of atopic heredity and formula received), and notably higher than among non-Hispanic Caucasians of the same age (2.82%).
Although not generalizable to the Philippines or the United States and Germany as a whole, this study suggests that people of Filipino descent may have some predisposition for AD. Nevertheless, although there may be some degree of uncertainty regarding the cumulative incidence of AD, the use of PHF-W remained cost saving when the 6-year cumulative incidence was 8.4%.
Little evidence is available regarding the severity of AD in the Philippines and elsewhere. In the present analysis, it was assumed that AD would be moderate and severe in 25% and 15% of the cases in children younger than 2 years, respectively, and in 10% and 5% of the cases in children aged 2 to 6 years, respectively. In ISAAC [27] , severe AD (defined as current eczema associated with sleep disturbance one or more nights per week) accounted for 6% of the AD cases in German children aged 6 to 7 years, with corresponding figures for Malaysia, Indonesia, Singapore, and Vietnam ranging from 6% to 13% (data for the Philippines for this age group were not reported in ISAAC). In a survey of knowledge, attitudes, and practices of Southeast Asian dermatologists in the management of AD [34] , it was reported than only 2% of the patients with AD first presented with severe disease (mild cases accounted for 21% of the cases, and the balance, 76%, was considered of moderate severity). Thus, the assumptions made in the present analysis may be considered reasonable.
Treatment and resource use patterns remain largely poorly documented in the Philippines. In the present analysis, the management of AD was modeled using simplified algorithms that reflected relatively intensive care. In addition, the present analysis assumed that urban children with AD would be seen by medical professionals in proportion equal to that reported in Germany. However, a search of the literature identified one study on treatment patterns of the management of AD [34] . This survey of 42 surveyed Filipino dermatologists suggests that the management of AD may be relatively intensive in the Philippines. Specifically, moisturizers were reported to be almost universally used by the surveyed dermatologists. Approximately 30%, 50%, and 20% of the participants reported using topical steroids in infants with AD with mild, moderate, and severe disease, respectively. Low-potency topical corticosteroids were used most frequently (86%) in infants and children. Seventy-four percent of the dermatologists reported "always" using oral antihistamines to treat patients with AD, whereas 24% reported using it "sometimes." In severe AD, oral steroids were used by 86% of the dermatologists. Phototherapy was reportedly used by 29% of the dermatologists. Finally, none of these 42 surveyed dermatologists recommended the use of alternative medicines such as traditional Chinese medicines and homeopathy.
Food allergens, especially cow's milk, are often implicated as major triggers for AD flare ups in Filipino infants. Whether confirmed by diagnostic testing or suspected by clinical history, shifting formulas to one not containing cow's milk is a common practice among parents and clinical practitioners. In the present model, it was assumed that soy-based formulas would be used as one of the methods to manage AD triggered by a confirmed or suspected cow's milk allergy. However, soy-based formulas, as a rule, are not recommended for the treatment of AD unless a substitute formula is necessary for children allergic to cow's milk with moderate to severe AD who cannot afford the cost of extensively hydrolyzed formulas. Hence, this assumption was adopted on the basis of discussions among the authors and the other clinical expert to reflect current practice in the Philippines. In addition, soy formula was assumed to be the least expensive formula dietary modification available in the Philippines. In that sense, its use in the model may underestimate the cost of managing AD. This study did not account for any wastage factor while estimating costs for formula consumption. However, variations in formula costs in sensitivity analysis can be used as a substitute to formula wastage to assess the degree to which this limitation affects the results.
This study was conservative in additional respects. First, any effects of AD in the past 6 years were excluded. In addition, any other allergic manifestations (within and after the initial 6 years) that may be preventable with the use of PHF-W were ignored. The effect on the AD child's parents' productivity (and in particular the lost productivity while at work) was only partially considered. The effect of AD on parents' QOL was ignored entirely. Finally, the excess cost of PHF-W formula in children who initiated PHF-W was included even after the 17-week prevention period (among those who did not experience AD and those who experienced AD but were treated using pharmacotherapy) because it was assumed that parents would continue this formula up to month 24. In reality, however, it is possible that parents may decide to switch to SF after 17 weeks without any loss of prevention against AD.
Conclusions
The present analysis used modeling techniques to assess the long-term cost-effectiveness of preventing AD via early nutritional intervention with PHF-W versus SF in healthy infants with atopic heredity who are not exclusively breast-fed. The analysis was conducted from a Filipino societal perspective, focusing on the urban population. The results suggest that the use of PHF-W in this defined patient population may be a dominant strategy relative to the use of SF because it reduces the clinical and QOL burden of AD while decreasing overall costs, even after the inclusion of formula costs. The results provide valuable insights into long-term prevention of AD in children that can be helpful for physicians. The results may also help government/private health plans make decisions regarding reimbursement/coverage policies for infant formulas among newborns who are at risk of developing AD and are not exclusively breast-fed. Although the analysis was conducted on the basis of limited evidence, various sensitivity and scenario analyses show that these conclusions may be robust. Nevertheless, additional research regarding the epidemiology, severity, treatment patterns, and resource use associated with the prevention and treatment of AD in the Philippines are warranted.
